中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2012年
4期
32-34
,共3页
进展期胃癌%替吉奥%临床观察
進展期胃癌%替吉奧%臨床觀察
진전기위암%체길오%림상관찰
Advanced gastric cancer%S-1%Clinical observation
目的 观察替吉奥(S-1)单药治疗进展期胃癌的近期疗效及不良反应.方法 16例进展期胃癌患者应用替吉奥胶囊80mg/(m2·d),分早晚两次口服,第1 ～14天,停药7d,21 d为1个周期.至少服用2个周期后复查肿瘤标志物及CT评价疗效.结果 临床受益率为68.8％,中位无进展生存期(mPFS)为4.3个月.主要不良反应为骨髓抑制及消化道反应,所有患者均未出现Ⅲ度以上不良反应,均为Ⅰ/Ⅱ度.结论 替吉奥单药治疗进展期胃癌临床受益率高,不良反应轻,患者耐受性好.
目的 觀察替吉奧(S-1)單藥治療進展期胃癌的近期療效及不良反應.方法 16例進展期胃癌患者應用替吉奧膠囊80mg/(m2·d),分早晚兩次口服,第1 ～14天,停藥7d,21 d為1箇週期.至少服用2箇週期後複查腫瘤標誌物及CT評價療效.結果 臨床受益率為68.8％,中位無進展生存期(mPFS)為4.3箇月.主要不良反應為骨髓抑製及消化道反應,所有患者均未齣現Ⅲ度以上不良反應,均為Ⅰ/Ⅱ度.結論 替吉奧單藥治療進展期胃癌臨床受益率高,不良反應輕,患者耐受性好.
목적 관찰체길오(S-1)단약치료진전기위암적근기료효급불량반응.방법 16례진전기위암환자응용체길오효낭80mg/(m2·d),분조만량차구복,제1 ～14천,정약7d,21 d위1개주기.지소복용2개주기후복사종류표지물급CT평개료효.결과 림상수익솔위68.8％,중위무진전생존기(mPFS)위4.3개월.주요불량반응위골수억제급소화도반응,소유환자균미출현Ⅲ도이상불량반응,균위Ⅰ/Ⅱ도.결론 체길오단약치료진전기위암림상수익솔고,불량반응경,환자내수성호.
Objective To observe the recent effect and adverse reactions of S-1 in the treatment of advanced gastric cancer.Methods Sixteen patients with advanced gastric cancer were treated with S1 80 mg/(m2,d),twice a day,d1-14,21 days for a cycle.Tumor markers and CT were detected to evaluate efficacy after two cycles.Results Clinical benefit rate was 68.8％,the median progression-free survival was 4.3 months.The major toxicities were bone marrow suppression and gastrointestinal reactions.All toxicities were grade Ⅰ/Ⅱ,not grade Ⅲ.Conclusions S-1 in the treatment of advanced gastric cancer has high clinical benefit rate,less adverse reactions and can be well tolerated in patients.
